NCT07229820
Efficacy and Safety of ZSP1273 in Adolecent 12-17 Years Old With Influenza A
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 13 words
- Trial completed
- Study completion date changed from estimate of Dec 31, 2025 to Jan 25, 2026
- Study title revised
Minor Trial status: Recruiting to Active, Not Recruitingv3 Show 4 more changesShow less
- Enrollment target: estimated 150 to confirmed 157
- Primary completion date: Jul 17, 2026 to Dec 22, 2025
- Study completion date: Nov 17, 2026 to Dec 31, 2025
- Site details revised
- Minor Start date changed from estimate of Nov 30, 2025 to Nov 8, 2025v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Time to Alleviation of Symptoms
Timeframe: DAY1~DAY15
Secondary (2)
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Plasma concentrations of ZSP1273
Arms and interventions
ZSP1273Experimental
PlaceboPlacebo comparator
Drugs: ZSP1273, Placebo
Sites
1 site in 1 country
- Ruijin HospitalShanghai, China